Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
- Author:
Sang Ouk CHIN
1
;
Cheol Ryong KU
;
Byung Joon KIM
;
Sung Woon KIM
;
Kyeong Hye PARK
;
Kee Ho SONG
;
Seungjoon OH
;
Hyun Koo YOON
;
Eun Jig LEE
;
Jung Min LEE
;
Jung Soo LIM
;
Jung Hee KIM
;
Kwang Joon KIM
;
Heung Yong JIN
;
Dae Jung KIM
;
Kyung Ae LEE
;
Seong Su MOON
;
Dong Jun LIM
;
Dong Yeob SHIN
;
Se Hwa KIM
;
Min Jeong KWON
;
Ha Young KIM
;
Jin Hwa KIM
;
Dong Sun KIM
;
Chong Hwa KIM
Author Information
- Publication Type:Review
- Keywords: Acromegaly; Somatostatin analogues; Octreotide; Lanreotide; Pasireotide
- MeSH: Acromegaly; Consensus; Expert Testimony; Insurance Coverage; Insurance, Health; Octreotide; Somatostatin
- From:Endocrinology and Metabolism 2019;34(1):53-62
- CountryRepublic of Korea
- Language:English
- Abstract: The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.
